Botanical Derived

Dihydroberberine

Berberine derivative compound

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

100-300 mg/day

watchEffect Window

weeks

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Dihydroberberine is a small molecule, salt, or polymer used for targeted metabolic or digestive effects. It is used to influence specific pathways rather than general nutrition.

Evidence varies widely by compound. Some have controlled human data for specific outcomes such as lipid markers, glycemic response, or symptom relief, while others are supported mainly by mechanistic studies. Minority uses include inflammation modulation and antioxidant effects. Dose, formulation, and safety constraints often determine whether measurable benefits occur.

Reduced-berberine analog expected to influence insulin and lipid pathways. Human evidence remains preliminary.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Fasting glucose and lipid trend
  • Metabolic burden reduction (proxy)

Secondary Outcomes

  • GI tolerability
  • Indirect wellbeing outcomes

Safety

Contraindications and Interactions

Contraindications

  • Severe hypoglycemia history
  • Pregnancy/lactation
  • Significant liver dysfunction

Side effects

  • GI intolerance
  • Constipation or loose stool
  • Headache

Interactions

  • Metformin and GLP-1 agents
  • Other glucose-lowering compounds
  • Drug metabolism-sensitive agents

Avoid if

  • Unstable diabetes
  • Liver dysfunction
  • Complex medication regimens

Evidence

Study-level References

dihydroberberine-SRC-001Small RCTs and comparative trials
Sourceopen_in_new

PMID: 38891813

Population: Adults with metabolic dysregulation

Dose protocol: Oral derivative dosing, variable standardization

Key findings: Consistent direction toward metabolic improvement signal in many but not all studies.

Notes: Small samples and heterogeneity across formulations.

Paper content

Consistent direction toward metabolic improvement signal in many but not all studies.

dihydroberberine-SRC-002Review and pharmacology synthesis
Sourceopen_in_new

PMID: 34386321

Population: Supplement users and clinical co-therapy scenarios

Dose protocol: Non-standardized commercial preparations

Key findings: Elevated monitoring burden for glycemic co-therapies.

Notes: Interaction rates are likely underreported in observational settings.

Paper content

Elevated monitoring burden for glycemic co-therapies.

dihydroberberine-SRC-003Randomized, double-blind, crossover pilot trial.
Sourceopen_in_new

Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients. 2022;14(1):124. doi:10.3390/nu14010124. PMID:35010998.

Population: Healthy young men.

Dose protocol: 100 mg and 200 mg dihydroberberine versus 500 mg berberine in a single-day crossover

Key findings: Both dihydroberberine doses produced significantly higher plasma berberine levels than 500 mg standard berberine.

Notes: Very small pilot (n=5) confirms pharmacokinetic advantage but cannot address clinical metabolic outcomes.

Paper content

This randomized, double-blind, crossover pilot trial compared plasma berberine pharmacokinetics and acute glycemic effects across placebo, 500 mg berberine, and 100 or 200 mg dihydroberberine in five healthy men. Both dihydroberberine doses produced significantly higher plasma berberine levels than the standard 500 mg berberine dose, confirming the enhanced bioavailability of dihydroberberine in humans. However, the acute glycemic challenge did not reveal statistically significant differences between conditions, likely limited by the very small sample size and single-day protocol. The study provides direct human pharmacokinetic evidence supporting the fivefold bioavailability advantage of dihydroberberine, but no conclusions about clinical metabolic outcomes can be drawn.

Guides

Setup

Help